Bristol Myers Squibb Company (NYSE:BMY) Shares Acquired by Mesirow Financial Investment Management Inc.

Key Points

• Mesirow Financial Investment Management Inc. has increased its stake in Bristol Myers Squibb (NYSE:BMY) by 16.7%, now holding 45,545 shares worth approximately $2.78 million.
• Analysts hold a mixed outlook on Bristol Myers Squibb, with recent price targets set between $34.00 and $55.00, and a consensus rating of "Hold."
• Bristol Myers Squibb recently declared a quarterly dividend of $0.62 per share, resulting in an annualized payout of $2.48 and a yield of 5.39%.

Mesirow Financial Investment Management Inc. lifted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 16.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 45,545 shares of the biopharmaceutical company's stock after acquiring an additional 6,526 shares during the quarter. Mesirow Financial Investment Management Inc.'s holdings in Bristol Myers Squibb were worth $2,778,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Thoroughbred Financial Services LLC grew its stake in shares of Bristol Myers Squibb by 1.1% in the fourth quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company's stock worth $1,004,000 after acquiring an additional 190 shares during the last quarter. Marcum Wealth LLC grew its stake in shares of Bristol Myers Squibb by 1.0% in the first quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock worth $1,177,000 after acquiring an additional 193 shares during the last quarter. Beacon Investment Advisory Services Inc. grew its stake in shares of Bristol Myers Squibb by 2.7% in the first quarter. Beacon Investment Advisory Services Inc. now owns 8,063 shares of the biopharmaceutical company's stock worth $492,000 after acquiring an additional 212 shares during the last quarter. 1858 Wealth Management LLC grew its stake in shares of Bristol Myers Squibb by 3.6% in the first quarter. 1858 Wealth Management LLC now owns 6,421 shares of the biopharmaceutical company's stock worth $392,000 after acquiring an additional 221 shares during the last quarter. Finally, Tompkins Financial Corp grew its stake in shares of Bristol Myers Squibb by 2.5% in the first quarter. Tompkins Financial Corp now owns 9,151 shares of the biopharmaceutical company's stock worth $558,000 after acquiring an additional 225 shares during the last quarter. Institutional investors own 76.41% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BMY. Citigroup cut their target price on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research note on Friday. Morgan Stanley reaffirmed a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday. UBS Group dropped their price objective on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. William Blair reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Finally, Piper Sandler initiated coverage on Bristol Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $57.33.

Bristol Myers Squibb Price Performance

NYSE BMY traded up $0.94 during trading on Friday, hitting $44.25. 18,626,740 shares of the stock traded hands, compared to its average volume of 12,693,902. The company has a market capitalization of $90.05 billion, a P/E ratio of 17.84, a price-to-earnings-growth ratio of 2.35 and a beta of 0.36. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65. The firm has a 50-day simple moving average of $47.51 and a 200-day simple moving average of $52.28. Bristol Myers Squibb Company has a 12-month low of $42.96 and a 12-month high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.60% and a net margin of 10.58%. The firm had revenue of $12.27 billion during the quarter, compared to analysts' expectations of $11.32 billion. During the same quarter in the previous year, the business earned $2.07 EPS. The company's quarterly revenue was up .6% on a year-over-year basis. As a group, analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were given a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.6%. The ex-dividend date of this dividend was Thursday, July 3rd. Bristol Myers Squibb's payout ratio is presently 100.00%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.